伏妥昔單抗
外觀
維基百科,自由的百科全書
單株抗體 | |
---|---|
種類 | 完整抗體 |
目標 | HER1 |
臨床資料 | |
其他名稱 | 992 DS |
ATC碼 |
|
識別資訊 | |
CAS號 | 1310460-85-5 |
ChemSpider |
|
UNII | |
化學資訊 | |
化學式 | C6468H10002N1724O2055S46 |
摩爾質量 | 146,269.94 g·mol−1 |
伏妥昔單抗(INN:futuximab,開發代號:992 DS)是一種嵌合單株抗體,設計用於治療癌症。[1]它充當免疫調節劑並與 HER1 結合。[2][3]
該藥物由Symphogen開發。
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2).
- ^ Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J. Neurooncol. July 2018, 138 (3): 489–498. PMC 5999169 . PMID 29564747. doi:10.1007/s11060-018-2832-6.
血管生成素(英語:Angiopoietin receptor) |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CNTF(英語:Ciliary neurotrophic factor receptor) | |||||||||||
EGF(ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met)(英語:Hepatocyte growth factor receptor) |
| ||||||||||
IGF(英語:Somatomedin receptor) |
| ||||||||||
LNGF (p75NTR)(英語:Low-affinity nerve growth factor receptor) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL)(英語:RET proto-oncogene) |
| ||||||||||
SCF (c-Kit)(英語:CD117) |
| ||||||||||
TGFβ(英語:Transforming growth factor beta receptor) |
| ||||||||||
Trk |
| ||||||||||
VEGF(英語:Vascular endothelial growth factor receptor) |
| ||||||||||
其他 |
| ||||||||||